STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma
European Journal of Haematology · 2026-07 · 117 (1) · 258-266
DOI: 10.1111/ejh.70174 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 08.04.2026. Verfasst von Matthew T Ye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, STAT3 Transcription Factor, Mutation, STAT5 Transcription Factor. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Introduction
Plasma cell myeloma is a heterogeneous hematologic malignancy characterized by clonal expansion of plasma cells. While RAS‐MAPK pathway mutations are known high‐risk features, the clinical relevance of STAT3 / STAT5 mutations remains unclear.
Method
We analyzed 16 myeloma patients with STAT3 / STAT5 mutations identified by next‐generation sequencing (9 STAT3 , 5 STAT5A , 2 STAT5B ) and compared them with 32 mutation‐negative controls.
Results
STAT3 / STAT5 mutations were present at initial diagnosis in all eight patients with available initial sequencing data, suggesting these are early events in pathogenesis. STAT3 / STAT5 mutations were the sole mutations in five patients, while 10 had co‐mutations, most frequently in KRAS / NRAS ( n = 5) and TP53 ( n = 3). In co‐mutated cases, STAT3 / STAT5 represented the dominant clone in 4 and co‐dominant in 6. All mutations were missense, with 63% involving the SH2 domain. Compared with controls, STAT3 / STAT5 ‐mutated patients had higher serum lactate dehydrogenase levels, higher incidence of IgA paraprotein, higher R‐ISS stage, more complex karyotype, and frequent CKS1B gain/amplification. Overall survival was significantly shorter in patients with STAT3 / STAT5 mutations (median 42 vs. 72 months, p < 0.0001).
Conclusion
STAT3 / STAT5 mutations are early, dominant, and potentially pathogenic events in plasma cell myeloma. Their association with adverse clinical features and inferior survival supports their routine assessment and potential therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
ORCID-Profile: Matthew T Ye
Zitieren
APA
Ye, M. T., Zuo, Z., Calin, S., Yang, Y., & You, M. J. (2026). STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma. European Journal of Haematology, 117(1), 258-266. https://doi.org/10.1111/ejh.70174
Vancouver
Ye MT, Zuo Z, Calin S, Yang Y, You MJ. STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma. European Journal of Haematology. 2026;117(1):258-266. doi:10.1111/ejh.70174
BibTeX
@article{Ye2026,
author = {Ye, Matthew T and Zuo, Zhuang and Calin, Steliana and Yang, Yaling and You, M James},
title = {STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {258--266},
doi = {10.1111/ejh.70174}
}
EUVIMED